$RTGN
RetinalGenix Technologies Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040743 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $486.8K $595.7K $271.8K
YoY Change 36.66% 119.15%
% of Gross Profit
Research & Development $53.90K $89.78K $198.5K
YoY Change -83.04% -54.77% -1.19%
% of Gross Profit
Depreciation & Amortization $20.00 $30.00 $30.00
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $540.7K $685.5K $2.503M
YoY Change -19.78% -72.62% 355.26%
Operating Profit
YoY Change
Interest Expense -$960.00 $960.00 $1.261K
YoY Change 0.0% -23.87% 6.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$541.6K -$686.5K -$2.504M
YoY Change -19.75% -72.59%
Income Tax
% Of Pretax Income
Net Earnings -$541.6K -$686.5K -$2.504M
YoY Change -19.75% -72.59% 354.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 -$0.15
Diluted Earnings Per Share -$0.03 -$0.04 -$0.15
COMMON SHARES
Basic Shares Outstanding 17.59M shares 17.27M shares 16.64M shares
Diluted Shares Outstanding 17.28M shares 16.56M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $40.00 $3.630K
YoY Change -100.0% -98.9%
Cash & Equivalents $44.00 $3.632K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.00 $3.632K
YoY Change -98.79%
LONG-TERM ASSETS
Property, Plant & Equipment $156.00 $181.00 $282.00
YoY Change -39.06% -35.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $156.00 $181.00 $282.00
YoY Change -39.06% -35.82%
TOTAL ASSETS
Total Short-Term Assets $44.00 $3.632K
Total Long-Term Assets $156.00 $181.00 $282.00
Total Assets $156.00 $225.00 $3.914K
YoY Change -46.94% -94.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $884.9K $751.4K $366.7K
YoY Change 86.11% 104.91%
Accrued Expenses $11.60K $10.64K $6.800K
YoY Change 49.48% 56.47%
Deferred Revenue
YoY Change
Short-Term Debt $49.00K $49.00K $48.00K
YoY Change 0.0% 2.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.406M $1.083M $1.063M
YoY Change 31.46% 1.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.406M $1.083M $1.063M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.406M $1.083M $1.063M
YoY Change 31.52% 1.89%
SHAREHOLDERS EQUITY
Retained Earnings -$11.11M -$10.57M -$8.300M
YoY Change 23.19% 27.33%
Common Stock $1.819K $1.814K $1.724K
YoY Change 2.02% 5.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.406M -$1.083M -$1.059M
YoY Change
Total Liabilities & Shareholders Equity $156.00 $225.00 $3.914K
YoY Change -46.94% -94.25%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$541.6K -$686.5K -$2.504M
YoY Change -19.75% -72.59% 354.52%
Depreciation, Depletion And Amortization $20.00 $30.00 $30.00
YoY Change 0.0% 0.0%
Cash From Operating Activities -$186.7K $39.75K -$166.0K
YoY Change 461.65% -123.94%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $310.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$310.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 186.7K -41.62K 165.0K
YoY Change 529.5% -125.22%
NET CHANGE
Cash From Operating Activities -186.7K 39.75K -166.0K
Cash From Investing Activities 0.000 -310.0
Cash From Financing Activities 186.7K -41.62K 165.0K
Net Change In Cash -40.00 -1.870K -1.320K
YoY Change -98.89% 41.67%
FREE CASH FLOW
Cash From Operating Activities -$186.7K $39.75K -$166.0K
Capital Expenditures $0.00 $310.00
Free Cash Flow -$186.7K -$166.4K
YoY Change 461.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001836295
CY2023Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
usd
RTGN Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
RTGN Offset Of Note Payable Affiliates Through The Exercise Of Warrants
OffsetOfNotePayableAffiliatesThroughTheExerciseOfWarrants
usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2022 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-258528
dei Entity Registrant Name
EntityRegistrantName
RETINALGENIX TECHNOLOGIES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3936890
dei Entity Address Address Line1
EntityAddressAddressLine1
1450 North McDowell Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
Petaluma
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94954
dei City Area Code
CityAreaCode
(415)
dei Local Phone Number
LocalPhoneNumber
578-9583
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17588811 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
44 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256 usd
CY2023Q3 us-gaap Assets
Assets
225 usd
CY2022Q4 us-gaap Assets
Assets
294 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
751388 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
475480 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
49000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
49000 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
10639 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1082755 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069357 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17588811 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17588811 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17272116 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17272116 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1814 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1783 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9483215 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7947460 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10567559 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9018306 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1082530 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
167046 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
201148 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
89778 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
198504 usd
CY2022Q3 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2032889 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
428683 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
70689 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
685507 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2503230 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
960 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1261 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-686467 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2504491 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17275635 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17275635 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16564317 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16564317 shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
490385 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
529728 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
470287 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
491436 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2032889 usd
us-gaap Share Based Compensation
ShareBasedCompensation
585701 usd
us-gaap Share Based Compensation
ShareBasedCompensation
180791 usd
us-gaap Operating Expenses
OperatingExpenses
1546373 usd
us-gaap Operating Expenses
OperatingExpenses
3234844 usd
us-gaap Interest Expense
InterestExpense
2880 usd
us-gaap Interest Expense
InterestExpense
4180 usd
us-gaap Net Income Loss
NetIncomeLoss
-1549253 usd
us-gaap Net Income Loss
NetIncomeLoss
-3239044 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17273289 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17273289 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15127445 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15127445 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-464675 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55051 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60500 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-375199 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-724323 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55051 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
353432 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-359335 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-675175 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70689 usd
CY2022Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2000000 usd
CY2022Q3 RTGN Stock Issued During Period Value Warrant And Stock Options Exercised
StockIssuedDuringPeriodValueWarrantAndStockOptionsExercised
50000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2504491 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1058977 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1069063 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
78509 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-510643 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1501197 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
78509 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-352143 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1774831 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1774831 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
428683 usd
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
950086 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-686467 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1082530 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1082530 usd
us-gaap Net Income Loss
NetIncomeLoss
-1549253 usd
us-gaap Net Income Loss
NetIncomeLoss
-3239044 usd
us-gaap Share Based Compensation
ShareBasedCompensation
585701 usd
us-gaap Share Based Compensation
ShareBasedCompensation
180791 usd
RTGN Acquired Inprocess Research And Development Through Issuance Of Common Stock
AcquiredInprocessResearchAndDevelopmentThroughIssuanceOfCommonStock
2000000 usd
us-gaap Depreciation
Depreciation
75 usd
us-gaap Depreciation
Depreciation
25 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
523053 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
772581 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
275908 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
115405 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2880 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
4180 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1387617 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3072982 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-161636 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-166062 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
307 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60500 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
161642 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
79534 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161642 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165034 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1315 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4947 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3632 usd
us-gaap Stock Issued1
StockIssued1
950086 usd
us-gaap Stock Issued1
StockIssued1
353432 usd
RTGN Offset Of Note Payable Affiliates Through The Exercise Of Warrants
OffsetOfNotePayableAffiliatesThroughTheExerciseOfWarrants
25000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10568000 usd
CY2023Q3 us-gaap Cash
Cash
44 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1083000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1069000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zjdsFk1jrP73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_86A_zDu5EV0dtGuj">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company’s consolidated financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify; text-indent: -16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Share Based Compensation
ShareBasedCompensation
585701 usd
us-gaap Share Based Compensation
ShareBasedCompensation
180791 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
420000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1882500 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
502500 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2360000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
300000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2660000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0285 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Share Price
SharePrice
3.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.56
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0219 pure
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Price
SharePrice
1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
199000 shares
CY2021Q4 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.07
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
12500 shares
CY2022 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
1.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
25000 shares
CY2022 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised
1.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
161500 shares
CY2022Q4 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
11500 shares
RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled
1.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
150000 shares
CY2023Q3 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.10
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.10
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
150000 shares
RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P4Y9M18D
CY2023Q3 RTGN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
150000 shares
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
74000 usd
CY2021Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2021 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-12-31
CY2021 RTGN Debt Instrument Extended Maturity Date
DebtInstrumentExtendedMaturityDate
2023-12-31
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25000 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
49000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
49000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
2880 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
4180 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
10639 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7759 usd

Files In Submission

Name View Source Status
0001493152-23-040743-index-headers.html Edgar Link pending
0001493152-23-040743-index.html Edgar Link pending
0001493152-23-040743.txt Edgar Link pending
0001493152-23-040743-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rtgn-20230930.xsd Edgar Link pending
Show.js Edgar Link pending
rtgn-20230930_def.xml Edgar Link unprocessable
rtgn-20230930_lab.xml Edgar Link unprocessable
rtgn-20230930_cal.xml Edgar Link unprocessable
rtgn-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed